Cardiac troponin T and familial hypertrophic cardiomyopathy: an energetic affair

Abstract

It has long been noted that while patients with familial hypertrophic cardiomyopathy due to cardiac troponin T (cTnT) mutations often suffer sudden cardiac death, they do not develop significant ventricular hypertrophy, suggesting that a distinct cellular mechanism apart from alterations in myocardial contractility is responsible. A new study has revealed that a single missense mutation in cTnT causes a striking disruption to energy metabolism, leading to cardiomyopathy.

The hallmarks of familial hypertrophic cardiomyopathy (FHC) are unexplained hypertrophy of the left ventricle and of the interventricular septum without dilatation of the ventricular chamber, and cardiac myocyte disarray (reviewed in refs. 1–5). A prominent feature in nearly all patients with FHC is abnormal diastolic function due to impaired relaxation and reduced compliance (6). FHC is a frequent cause of sudden cardiac death (SCD), particularly in young individuals and competitive athletes (7). The disease is phenotypically heterogeneous. Some individuals remain asymptomatic throughout life, and others develop progressive symptoms with or without heart failure or experience SCD. In some families, FHC is a malignant disease with a high incidence of SCD. Eleven genes are involved in the pure form of the disease, all encoding components of the contractile apparatus of the cardiac myocyte (reviewed in ref. 8). Genotype-phenotype analyses revealed some significant differences in prognosis between the different FHC genes and between different mutations in the same gene (reviewed in refs. 3, 9). Cardiac troponin T (cTnT) mutations in particular predispose the affected patients to SCD, and one of the most malignant mutations in FHC is a missense mutation that results in an exchange of a glutamine for an arginine at residue 92 (R92Q), in the tail portion of cTnT (10). Individuals bearing this mutation are at high risk for SCD, despite the absence of overt ventricular hypertrophy. The work of Javadpour et al., reported in this issue of the JCI (11), describes sound and consistent energetic and mechanical data that provide insight into the mechanism by which patients develop defective energy metabolism and cardiomyopathy due to an FHC-causing mutation in cTnT.

Troponin T is a key regulator of cardiac contraction

In striated muscles, troponin T (TnT), together with troponin C (TnC), troponin I (TnI), and tropomyosin, belongs to the group of so-called regulatory proteins of the sarcomere. Early studies have established a role for each of them. TnI prevents the interaction of actin with myosin heads, an inhibition relieved by calcium binding to TnC. TnT binds the two other troponins to tropomyosin, which itself binds the whole protein complex to the actin thin filament. In this model, TnT behaves simply as a passive link between other more functionally implicated proteins. This simplistic scheme has been questioned recently by a number of elegant biochemical and biophysical studies (12–17). TnT now appears to be the most important regulatory protein of the sarcomere, which could explain why it exists as so many alternatively spliced isoforms. Experiments using peptides expressed in Escherichia coli have shown that a portion of the TnT tail (residues 70–170) is crucial for TnT binding to tropomyosin, tropomyosin binding to actin, and stabilization of the complex with overlapping tropomyosin extremities. FHC mutations localized between residues 92 and 110 alter these TnT functions, whereas those outside the region are neutral (12). More importantly, the tail portion of the TnT molecule also seems to be essential for regulating the function of the whole troponin-tropomyosin complex. Indeed, it regulates the position of the complex on the thin filament vis-à-vis the myosin heads by stabilizing either a blocked B-state of the filament — in which, in the absence of calcium, tropomyosin binds to the actin outer domain in a position where it prevents muscle contraction (13) — or a closed C-state in which actin-myosin interaction is still weak (16). A number of FHC mutations in this area would impair TnT function through alterations in TnT tail flexibility (17).

Functional and energetic consequences of the R92Q mutation

The R92Q missense mutation examined by Javadpour and colleagues in the present study (11) is located in a TnT domain that interacts with tropomyosin and that therefore is critical for cooperative actin binding and regulatory function. The functional consequences of this mutation have been extensively characterized in isolated myofibrils (reviewed in ref. 12) and transgenic mouse models (18, 19), but the results have varied according to the model system employed. For example, in cultured quail myotubes (20) and rat ventricular myocytes (21), the mutant TnT decreases the calcium sensitivity of force production, whereas in permeabilized rabbit cardiac fibers, the free-calcium concentration required for tension generation is significantly lower (22). These differences are not very surprising, considering the difficulties of working with a structure as complex as the myofibril. Recently, the R92Q mutation has been compared with the ΔLys-210 deletion, known to cause dilated cardiomyopathy in in vitro assays of ATPase activity and filament motility (23). Whereas the ΔLys-210 deletion gave a significantly reduced sliding speed as compared with wild-type TnT and produced less enhancement of ATPase at activating calcium concentrations, the inverse occurred with the R92Q mutation. At activating calcium concentrations, it enhanced thin-filament sliding velocity and activation of ATPase activity. Even more interestingly, at low calcium concentrations, it induced less inhibition of filament sliding velocity and of ATPase activity than did wild-type TnT, suggesting a global shift toward an increased function, regardless of the calcium concentration and therefore of the functional stage in the contraction-relaxation cycle.

Consistent with these observations, Javadpour et al. (11) show that the R92Q mutation, when expressed in the mouse heart (67% replacement of the wild-type protein), decreases the energetic driving force within cardiac myocytes (|ΔG_∼ATP| = free energy of ATP hydrolysis) by increasing ATP utilization, most likely because of a mutation-induced boosting of myofibrillar ATPase activity. Very interestingly, all mechanical parameters at the base-line calcium concentration of 2.5 mM were normal, except the maximum rate of left ventricular pressure decay (–dP/dt), which was decreased by 26%, indicative of diastolic dysfunction. This can be explained by the fact that the decrease in free energy released from ATP in R92Q brings the value of |ΔG_∼ATP| to 51.3 kJ/mol, below that required for the sarcoplasmic reticulum Ca²⁺-ATPase (SERCA) to function optimally (24). Therefore, it could be expected that left ventricular mechanical function would worsen when hearts are submitted to an increase in workload. Indeed, when hearts were perfused with 4 mM calcium, only a very small fall in free energy of ATP hydrolysis was observed, which could not even be transformed into an increase in mechanical work.

Is a mismatch in energy utilization a novel pathogenic mechanism in FHC?

A critical feature of this study is that measurements were taken in the intact heart, where the impact of small perturbations at the protein level can be summed over a large number of myofibrils (11). The results are important for a number of reasons. They extend in vitro data indicating that the R92Q TnT mutation enhances the activation of myofibrillar ATPase activity. However, it remains now to understand how mutations in the TnT tail, a portion of the TnT molecule that normally prevents ATPase activation, transforms this peptide into an activating molecule that finally results in a boost in overall myofibrillar ATPase activity. Another intriguing finding of the study is the inability of the mutated TnT to transduce the increase in calcium to increased contractile performance, which contrasts markedly with the effect of the R403Q α-myosin heavy chain mutation. In a more speculative way, one may wonder why adaptive mechanisms do not take place in the R92Q TnT mouse heart to reset |ΔG_∼ATP| at a normal level. This question may be related to that of why no overt ventricular hypertrophy is observed with this mutation and it can be hypothesized that both resetting of |ΔG_∼ATP| at a normal level and development of ventricular hypertrophy would further deteriorate the energetic cost for a given workload.

Another important finding of the study by Javadpour et al. (11) that could only be demonstrated using an in vivo model is that the deleterious effect of the mutation occurs particularly during increases in workload. An important next step will be to determine the incidence of SCD in these mice and to elucidate how it occurs. Confirmation that the energetic alterations are responsible for SCD would invite systematic investigation of whether genes that encode proteins involved in maintaining the energetic homeostasis of cardiac myocytes are modifier genes. The work of Javadpour et al. also provides a new framework for our understanding of a number of unresolved cases of diastolic dysfunction, although some findings may need some clarification, such as the unexpectedly small improvement of –dP/dt and the absence of an increase in end-diastolic pressure when hearts of R92Q mice are submitted to an increase in workload.

That such a pathophysiological process develops almost exclusively during an increase in workload in the absence of detectable cardiac hypertrophy points to the need to determine patients at high risk for SCD by performing investigations not only at rest but also during exercise. Such a need may be relevant not only to the screening of probands within an affected family but also to all individuals who play sports, and not only high-level athletes.

Footnotes

See the related article beginning on page 768.

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: familial hypertrophic cardiomyopathy (FHC); sudden cardiac death (SCD); troponin T (TnT); cardiac troponin T (cTnT); maximum rate of left ventricular pressure decay (–dP/dt).

References

1. Maron, BJ, Ferrans, VJ. Ultrastructural features of hypertrophied human ventricular myocardium. Prog. Cardiovasc. Dis. 1978. 21:207-238.
   View this article via: PubMed CrossRef Google Scholar
2. Komajda, M., and Grosgogeat, Y. 1990. Myocardiopathies. In Recherches en hypertrophie et insuffisances cardiaques. B. Swynghedauw, editor. INSERM/John Libbey Eurotext Ltd. Montrouge, France. 505–522.
3. Schwartz, K, Carrier, L, Guicheney, P, Komajda, M. Molecular basis of familial cardiomyopathies. Circulation. 1995. 91:532-540.
   View this article via: PubMed Google Scholar
4. Roberts, R, Sigwart, U. New concepts in hypertrophic cardiomyopathies, part I. Circulation. 2001. 104:2113-2116.
   View this article via: PubMed CrossRef Google Scholar
5. Roberts, R, Sigwart, U. New concepts in hypertrophic cardiomyopathies, part II. Circulation. 2001. 104:2249-2252.
   View this article via: PubMed CrossRef Google Scholar
6. Maron, BJ, et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1987. 10:733-742.
   View this article via: PubMed Google Scholar
7. McKenna, W, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am. J. Cardiol. 1981. 47:532-538.
   View this article via: PubMed CrossRef Google Scholar
8. Richard, P, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation. 2003. 107:2227-2232.
   View this article via: PubMed CrossRef Google Scholar
9. Redwood, CS, Moolman-Smook, JC, Watkins, H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc. Res. 1999. 44:20-36.
   View this article via: PubMed CrossRef Google Scholar
10. Watkins, H, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 1995. 332:1058-1064.
    View this article via: PubMed CrossRef Google Scholar
11. Javadpour, MM, Tardiff, JC, Pinz, I, Ingwall, JS. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J. Clin. Invest. 2003. 112:768-775. doi:10.1172/JCI200315967.
    View this article via: JCI PubMed Google Scholar
12. Palm, T, Graboski, S, Hitchcock-DeGregori, SE, Greenfeld, NJ. Disease-causing mutations in cardiac troponin T: identification of a critical tropomyosin-binding region. Biophys. J. 2001. 81:2827-2837.
    View this article via: PubMed Google Scholar
13. Tobacman, LS, et al. The troponin tail domain promotes a conformational state of the thin filament that suppresses myosin activity. J. Biol. Chem. 2002. 277:27636-27642.
    View this article via: PubMed CrossRef Google Scholar
14. Greenfield, NJ, Palm, T, Hitchcock-DeGregori, SE. Structure and interactions of the carboxyl terminus of striated muscle α-tropomyosin: it is important to be flexible. Biophys. J. 2002. 83:2754-2766.
    View this article via: PubMed Google Scholar
15. Gomes, AV, Guzman, G, Zhao, J, Potter, JD. Cardiac troponin T isoforms affect the Ca2+ sensitivity and inhibition of force development. J. Biol. Chem. 2002. 277:35341-35349.
    View this article via: PubMed CrossRef Google Scholar
16. Maytum, R, Geeves, MA, Lehrer, S. A modulatory role for the troponin T tail domain in thin filament regulation. J. Biol. Chem. 2002. 277:29774-29780.
    View this article via: PubMed CrossRef Google Scholar
17. Hinkle, A, Tobacman, LS. Folding and function of the troponin tail domain. J. Biol. Chem. 2003. 278:506-513.
    View this article via: PubMed CrossRef Google Scholar
18. Tardiff, JC, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J. Clin. Invest. 1998. 101:2800-2811.
    View this article via: JCI PubMed CrossRef Google Scholar
19. Lim, DS, et al. Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q92, responsible for human hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 2000. 32:365-374.
    View this article via: PubMed CrossRef Google Scholar
20. Sweeney, HL, Feng, HS, Yang, Z, Watkins, H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc. Natl. Acad. Sci. U. S. A. 1998. 95:14406-14410.
    View this article via: PubMed CrossRef Google Scholar
21. Rust, EM, Albayya, FP, Metzger, JM. Identification of a contractile deficit in adult cardiac-myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J. Clin. Invest. 1999. 103:1459-1467.
    View this article via: JCI PubMed CrossRef Google Scholar
22. Morimoto, S, Yanaga, F, Minakami, R, Ohtsuki, I. Ca²⁺-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am. J. Physiol. 1999. 275:C200-C20wil7.
23. Robinson, P, et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J. Biol. Chem. 2002. 277:40710-40716.
    View this article via: PubMed CrossRef Google Scholar
24. Tian, R, Ingwall, JS. Energetic basis for reduced contractile reserve in isolated rat hearts. Am. J. Physiol. 1996. 270:1207-1216.